Veracyte Reports Strong Q2 Growth with 27% Revenue Increase

Veracyte Sees Robust Q2 Growth with a 27% Revenue Increase

Veracyte, Inc., a global genomic diagnostics company, reported a strong second quarter in 2024, with a 27% increase in revenue to $114.4 million compared to the same period last year. The company's testing revenue saw a significant rise of 31%, primarily driven by the robust demand for its Decipher and Afirma tests.